Compare MWG & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWG | CDT |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | Singapore | United States |
| Employees | N/A | 4 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.9M |
| IPO Year | 2022 | N/A |
| Metric | MWG | CDT |
|---|---|---|
| Price | $1.36 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.4K | ★ 75.3K |
| Earning Date | 06-11-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.37 |
| 52 Week High | $2.49 | $11.00 |
| Indicator | MWG | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 31.61 | 33.19 |
| Support Level | $0.23 | $0.49 |
| Resistance Level | $2.20 | $1.22 |
| Average True Range (ATR) | 0.09 | 0.22 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 6.45 | 4.85 |
Multi Ways Holdings Ltd is a supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region. The wide variety of new and used heavy construction equipment for sale and rental by customers range from: earth-moving equipment such as bulldozers, off-terrain dump trucks, excavators and wheel loaders; material-handling equipment such as crawler cranes, rough terrain cranes, scissor lifts, forklifts, boom-lifts and telescopic handlers; road-building equipment such as motor graders, vibrating compactors, asphalt finishers, skid loaders, backhoe loaders, hand rollers and mini excavators; and generators and compressors, such as air compressors, generators, lighting towers and welding machines.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.